SCHEMBL915701

SCHEMBL915701

Nc1ccc(CCNC(=O)O)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESRRG P62508 1/20 0.55
HIF1A Q16665 1/20 0.51
GFER P55789 1/20 0.50
MAOB P27338 3/20 0.48
MAOA P21397 2/20 0.48
KDM4E B2RXH2 1/20 0.47
F13A1 P00488 1/20 0.47
CA12 O43570 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47
PPID Q08752 1/20 0.47
ST14 Q9Y5Y6 1/20 0.46
EPHX1 P07099 1/20 0.46
PLAAT3 P53816 1/20 0.45
PLAAT5 Q96KN8 1/20 0.45
PLAAT2 Q9NWW9 1/20 0.45
PLAAT4 Q9UL19 1/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
PRMT1 Q99873 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4802911 0.89 MAOB (0.52) GFERMAOBKDM4EEPHX1NPC1
SCHEMBL15940162 0.86 ESRRG (0.57) ESRRGHIF1AGFERMAOBMAOA
SCHEMBL26709576 0.86 ESRRG (0.57) ESRRGHIF1AGFERKDM4EF13A1
SCHEMBL15650955 0.84 MEN1 (0.63) ESRRGKDM4ECA12CA2CA9
SCHEMBL625333 0.84 ESRRG (0.55) ESRRGHIF1AGFERMAOBMAOA
SCHEMBL23111915 0.83 MCHR1 (0.50) HIF1AMAOBKDM4EF13A1CA12
SCHEMBL12532995 0.82 ESRRG (0.58) ESRRGHIF1AGFERMAOBMAOA
SCHEMBL2715966 0.82 KDM4E (0.70) ESRRGHIF1AGFERKDM4EF13A1
SCHEMBL160340 0.82 ESRRG (0.54) ESRRGHIF1AGFERMAOBMAOA
SCHEMBL1437502 0.82 KDM4E (0.69) ESRRGGFERKDM4EF13A1PLAAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230391730-A1 INHIBITORS OF THE BROMODOMAIN PHD FINGER TRANSCRIPTION FACTOR (BPTF) AS ANTI-CANCER AGENTS REGENTS OF THE UNIVERSITY OF MINNESOTA 2023-12-07 US disclosed
WO-2023220526-A1 COMPOSITIONS AND METHODS FOR MODULATING DOPAMINE RECEPTOR ACTIVITY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-11-16 WO disclosed
US-20230256106-A1 DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF COVAL BIOPHARMA (SHANGHAI) CO., LTD. (CN) 2023-08-17 US disclosed
EP-4225745-A1 ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME Athenex, Inc. (US) 2023-08-16 EP disclosed
EP-4181963-A1 DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF Coval Biopharma (Shanghai) Co., Ltd. (CN) 2023-05-24 EP disclosed
US-11649222-B2 Compounds UNIVERSITETET I OSLO (NO) 2023-05-16 US disclosed
US-11332452-B2 Pesticidal compositions and methods CORTEVA AGRISCIENCE LLC (US) 2022-05-17 US disclosed
US-20220143183-A1 PHOTOSWITCHABLE PROTACS AND SYNTHESIS AND USES THEREOF NEW YORK UNIVERSITY 2022-05-12 US disclosed
EP-3978488-A1 ZINC CHELATING COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTION Universitetet I Oslo (NO) 2022-04-06 EP disclosed
WO-2022012492-A1 DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF COVAL BIOPHARMA (SHANGHAI) CO., LTD. (CN) 2022-01-20 WO disclosed
CN-1477960-A EPA receptor inhibitors to treat rheumatoid arthritis 2004-02-25 CN disclosed
US-6605618-B2 Antidiabetic agents; hypoglycemic agents; anticholesterol agents; side effect reduction WYETH 2003-08-12 US disclosed
US-20030018045-A1 Heterocyclic beta-3 adrenergic receptor agonists WYETH (US) 2003-01-23 US disclosed
US-6451814-B1 SUBSTITUTED 4-((4-AMINO-5-HYDROXYPHENYL)-OXY-)PIPERIDINE ANALOGS; METABOLIC DISORDERS; ANTIDIABETIC AGENTS; ATHERO-SCLEROSIS, GASTROINTESTINAL DISORDERS, GLAUCOMA, NEUROGENETIC INFLAMMATION, OCULAR HYPERTENSION AND FREQUENT URINATION WYETH 2002-09-17 US disclosed
US-20020028832-A1 Heterocyclic beta-3 adrenergic receptor agonists AMERICAN HOME PRODUCTS CORPORATION (US) 2002-03-07 US disclosed
WO-2002006250-A1 SUBSTITUTED ARYLSULFIDES, ARYLSULFOXIDES AND ARYLSULFONES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS WYETH (US) 2002-01-24 WO disclosed
WO-2002006229-A2 HETEROCYCLIC BETA-3 ADRENERGIC RECEPTOR AGONISTS WYETH (US) 2002-01-24 WO disclosed
EP-1140855-A1 TETRAHYDROINDAZOLE DERIVATIVES AS LIGANDS FOR GABA-A ALPHA 5 RECEPTORS MERCK SHARP & DOHME LTD. (GB) 2001-10-10 EP disclosed
WO-2000040565-A1 TETRAHYDROINDAZOLE DERIVATIVES AS LIGANDS FOR GABA-A ALPHA 5 RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2000-07-13 WO disclosed
WO-1994018161-A1 SUBSTITUTED PHENYL SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY MERCK & CO., INC. (US) 1994-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230256106-A1 DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF TIE1, TEK, KDR ESRRG 1034/4885HIF1A 85/4885GFER 4019/4885
US-20030018045-A1 Heterocyclic beta-3 adrenergic receptor agonists ADRB2, ADRB1, ADRB3 ESRRG 698/4885HIF1A 1809/4885GFER 2251/4885
US-20220143183-A1 PHOTOSWITCHABLE PROTACS AND SYNTHESIS AND USES THEREOF MDM2, UBE3C, CUL1 ESRRG 899/4885HIF1A 1333/4885GFER 1972/4885
US-11332452-B2 Pesticidal compositions and methods ACHE, DDT, PLA2G2D ESRRG 3831/4885HIF1A 4866/4885GFER 959/4885
US-11649222-B2 Compounds SLC30A6, SLC39A11, SLC39A3 ESRRG 3087/4885HIF1A 3268/4885GFER 767/4885
US-20020028832-A1 Heterocyclic beta-3 adrenergic receptor agonists ADRB1, ADRB3, ADRB2 ESRRG 696/4885HIF1A 1565/4885GFER 2536/4885
US-20230391730-A1 INHIBITORS OF THE BROMODOMAIN PHD FINGER TRANSCRIPTION FACTOR (BPTF) AS ANTI-CANCER AGENTS BPTF, BRPF3, PHF6 ESRRG 1130/4885HIF1A 1194/4885GFER 3314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.